ClinicalTrials.gg
CompletedNCT07119450Updated Nov 21, 2025

The Study of [14C] GZR18

A Phase 1 interventional study of GZR18 injection、[14C]GZR18 injection in Overweight, Obese and Obesity, sponsored by Gan & Lee Pharmaceuticals.. Completed at 1 site in China. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-11-21.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Gan & Lee Pharmaceuticals. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing bofanglutide in Obesity — 3 open to participants now, 3 under way, 3 of them phase 3. bofanglutide · Obesity.

Enrollment
15th of 15
6 · median 140
Started
2025
with 5 others
Phase 1
7 of 15
none open now
Registered
7th of 15
by date
Lead sponsor
9 of 15
Gan & Lee Pharmaceuticals.

Among the 15 studies testing bofanglutide in Obesity, this one is the 15th largest by enrollment, is one of 6 that started in 2025, is one of 7 in phase 1, and was the 7th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 15 studies testing bofanglutide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About bofanglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 55 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing bofanglutide in Obesity, or all of them as a file.
02

Study summary

This trial is a Single-center, non-randomized, open-label, single-dose Mass Balance Study.

The study period of each subject consists of a screening period (D-21 to D-2), a baseline period (D-2 to D-1), a dosing and routine collection period (D1 to D36) and an intermittent collection and follow-up period (D36 to D78, during which subjects should visit the hospital once a week, 6 visits in total).

03

Conditions studied

  • Overweight
  • Obese
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 6 is below the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Gan & Lee Pharmaceuticals. is the lead sponsor of 29 studies on the registry; 14 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must be fully informed, know and understand the content, process and possible treatment-related adverse events (TRAEs) before the study, and voluntarily sign a written form;
  2. Chinese adult male subjects aged 18-55 (inclusive);
  3. Body weight ≥ 50 kg;
  4. Subjects with stable physical activity and lifestyle and relatively stable weight within 3 months prior to screening (as per inquiry);
  5. Subjects have no sperm donation plan within 6 months after the last dose, and subjects and their partners have no pregnancy plan throughout the study and within 6 months after the last dose and voluntarily take effective measures to avoid pregnancy of their partners.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with other diseases or medical history that may hinder the subject from following the study protocol and completing this study as judged by the investigator.
  2. Subjects with abnormalities in vital signs, physical examination, routine laboratory tests (hematology, urinalysis, stool analysis + occult blood, blood chemistry and coagulation function), chest X-ray (AP view) or abdominal B-scan ultrasonography at screening or baseline, which are deemed clinically significant by the investigator; subjects with (ALT), aspartate aminotransferase (AST) or total exceeding the normal range at screening/baseline, which are deemed clinically significant by the investigator.
  3. Subjects who suffer from dyspepsia, esophageal reflux, peptic ulcer or gallbladder disease within 3 months prior to dosing, or any gastrointestinal disease that may affect gastric emptying, or any surgical procedure (such as cholecystectomy, except for appendicitis surgery) that may affect drug metabolism or excretion; or plan to undergo surgery during the study.
  4. Subjects who used any prescription drugs, OTC drugs, Chinese herbal medicines, food supplements (including vitamins, health food, etc.) within 14 days before dosing, or have other non-drug therapeutic factors affecting drug absorption, distribution, metabolism and excretion.
  5. ubjects who have received any other drug or participated in any other interventional clinical study within 3 months prior to screening, or still within 5 half-lives of a previously administered investigational drug at screening, whichever is longer.
  6. Difficulty in blood collection or intolerance to venipuncture for blood collection.
  7. Subjects who smoked > 5 cigarettes/day on average (or used an equivalent amount of nicotine products) in 6 months prior to screening, or are unwilling to abstain from tobacco products during the study.
  8. Those who are not eligible for the study for other reasons as judged by the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    GZR18 injection、[14C]GZR18 injection

    Drug: GZR18 injection、[14C]GZR18 injection

Interventions

07

What researchers measure

Primary outcomes

  1. Primary Outcome Measure

    The total radioactivity recovery at each interval and the cumulative total radioactivity recovery in excreta (urine and feces).

    Time frame: Through study completion, an average of 1 year

  2. Primary Outcome Measure

    Percentage of parent drug and its metabolites (if applicable) in plasma in total radioactivity exposure in plasma; percentage of parent drug and its metabolites (if applicable) in urine and feces in administered dose; identification of major metabolites in plasma, urine, and feces.

    Time frame: Through study completion, an average of 1 year

  3. Primary Outcome Measure

    Peak Plasma Concentration (Cmax)

    Time frame: Through study completion, an average of 1 year

  4. Primary Outcome Measure

    Area under the plasma concentration versus time curve (AUC)

    Time frame: Through study completion, an average of 1 year

  5. Primary Outcome Measure

    Ratio of total radioactivity concentration in whole blood to plasma

    Time frame: Through study completion, an average of 1 year

  6. Primary Outcome Measure

    Time-To-Peak(Tmax)

    Time frame: Through study completion, an average of 1 year

  7. Primary Outcome Measure

    Mean Residence Time

    Time frame: Through study completion, an average of 1 year

  8. Primary Outcome Measure

    Half-Life Period(T1/2)

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. PK parameters of GZR18 and its metabolites (if applicable) in plasma

    Peak Plasma Concentration (Cmax)

    Time frame: Through study completion, an average of 1 year

  2. Safety Evaluation:Clinical safety evaluation during the study

    weight and height will be combined to report BMI in kg/m\^2

    Time frame: Average of 1 year

  3. PK parameters of GZR18 and its metabolites (if applicable) in plasma

    Area under the plasma concentration versus time curve (AUC)

    Time frame: Through study completion, an average of 1 year

  4. PK parameters of GZR18 and its metabolites (if applicable) in plasma

    Time-To-Peak(Tmax)

    Time frame: through study completion, an average of 1 year

  5. PK parameters of GZR18 and its metabolites (if applicable) in plasma

    Mean Residence Time

    Time frame: through study completion, an average of 1 year

  6. PK parameters of GZR18 and its metabolites (if applicable) in plasma

    Half-Life Period(T1/2)

    Time frame: through study completion, an average of 1 year

  7. Safety Evaluation:Clinical safety evaluation during the study

    laboratory tests (hematology, urinalysis, blood chemistry, coagulation function, stool analysis + occult blood and thyroid function)

    Time frame: Average of 1 year

08

Study locations

1 site
  • Study site 01
    Beijing, China
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Aug 2025, 3 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Aug 13, 2025
StartActual
May 7, 2025
Primary completionActual
Aug 13, 2025
CompletionActual
Aug 13, 2025
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07119450
Responsible party
Sponsor
First posted
Aug 13, 2025
Start date
May 7, 2025
Primary completion
Aug 13, 2025
Completion
Aug 13, 2025
Last update
Nov 21, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bofanglutide

Start the discussion